Perimeter receives FDA premarket approval for Claire

Executive Summary

• Perimeter Medical Imaging AI Inc. has received U.S. Food and Drug Administration (FDA) premarket approval for "Claire," the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.
• The approval follows a pivotal clinical trial demonstrating an 88.1% margin accuracy and a statistically significant reduction in residual cancer compared to the standard of care, supported by a $7.4-million grant from the Cancer Prevention and Research Institute of Texas.
• The company plans to begin a nationwide launch in the coming weeks, targeting an estimated 300,000 annual U.S. breast cancer surgeries, with the goal of reducing repeat surgeries which currently occur in approximately 20% of cases.

Key Details

• Product: Claire (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0).
• Regulatory Status: FDA Premarket Approval (PMA); previously held "Breakthrough Device Designation."
• Technology: Combines proprietary AI with patented wide-field Optical Coherence Tomography (OCT) imaging.
• Performance Metrics:
  • Delivers 10 times higher resolution than standard X-ray and ultrasound.
  • Imaging depth of two millimeters (clinically relevant margin width).
  • Pivotal trial showed 88.1% margin accuracy.
  • Demonstrated "supersuperiority" in achieving clear surgical margins compared to standard of care.
• Data Advantage: AI engine trained on a proprietary library of over two million breast tissue images.
• Regulatory Flexibility: A predetermined change control plan was authorized, allowing for planned AI enhancements without additional FDA interaction.
• Market Opportunity: Targets an estimated 300,000 annual U.S. breast cancer surgeries; potential for expansion into other cancer indications, biopsy procedures, and pathology applications.
• Funding Support: Pivotal trial supported by a $7.4-million (U.S.) grant from the Cancer Prevention and Research Institute of Texas.
• Commercialization: Nationwide launch planned for the coming weeks.

Notable Quotes

• Adrian Mendes, CEO: "Claire's FDA approval marks a major milestone in breast cancer care as we advance our goal of reducing repeat surgeries so that no patient has to be told, 'We didn't get it all.'"
• Dr. Alastair Thompson, Primary Principal Investigator: "Claire has the potential to become a new standard in breast surgical care, helping reduce re-excisions while improving patient outcomes."
• Chamath Palihapitiya, Investor: "I believe Perimeter is at the starting line of something truly transformational... This is exactly the kind of AI-driven innovation that can improve the standard of care by delivering measurable, real-world medical impacts."